



Systematic Review and Meta-Analysis on Role of Adiponectin to Leptin Ratio in Women with Polycystic Ovarian Syndrome



Methods

The method followed the PRISMA 2020 guidelines, and the databases were used to obtain eligible studies published up to February 2023.


PRISMA




Databases



ESHRE ASRM Rotterdam Guideline




I2 statistic Cochran's Q test



Funnel plot



The evaluation on publication bias



Objective

To consolidate the importance of the A:L (adiponectin to leptin) ratio as a potential and promising biomarker for PCOS.

PROSPERO

April 2, 2023
CRD42023411754

Data analysis was conducted with JASP 0.17.1, and statistical significance was characterized as a p-value below 0.05.

Results

Systematic Review


Study Characteristics

9 studies


Results of Studies in Meta-Analysis

7 studies

Each paper showed a reduced A:L ratio in women with PCOS.



A standardized mean difference (SMD) among PCOS and control groups of 0.49 (CI: 0.37-0.61).



The residual heterogeneity test


p-value = 0.069

No publication bias indication

Pre and post intervention

p-value = 0.002

Conclusion



The A:L ratio was notably lower in PCOS patients. Consequently, the A:L ratio holds promise as a novel and potential biomarker for PCOS.

